1 Boston Medical Center, Brookline, Boston, Mass; 2 Boston University School of Medicine, Boston, Mass Objectives: Statin use in patients with cerebrovascular disease undergoing carotid endarterectomy (CEA) has been advocated. However, the intensity of statin therapy and its effect on short and long-term outcomes after CEA are unclear.
Methods: OptumLabs Data Warehouse, a large database containing administrative claims on privately insured and Medicare Advantage enrollees, was queried to analyze the effect of statin use on stroke and myocardial infarction (MI) after CEA. Statin use and doses were analyzed at 30 and 90 days postoperatively. Statin use compared to no statin use was the primary analysis. Secondary analysis of high-dose statin use (for atorvastatin, simvastatin, and rosuvastatin) compared to standard dosing was also performed. High-dose statins were defined as atorvastatin $80 mg, simvastatin $80 mg, and rosuvastatin $20 mg. For long-term analysis, statin use was defined as an active prescription for at least one-third of the follow-up.
Results: There were 21,465 patients who underwent CEA from 2004 to 2014. Mean age was 70 years and 59.2% were male. Median followup was 2 years (range, 0.2-10 years) and mean Elixhauser index score was 4.1. Thirty-and 90-day postoperative stroke rates were 1.3% and 2.1%, and MI rates were 0.4% and 1.1%. Statin was prescribed on discharge in 85.5% of patients, and its distribution was atorvastatin, 35%; simvastatin, 35%; pravastatin, 11%; rosuvastatin, 10%; and lovastatin, 7%. Long-term statin use was seen in 62.6%. Postoperative statin compared to no statin use did not affect rates of 30 day stroke (odds ratio [OR], 0.78; 95% confidence interval [CI], 0.59-1.024; P ¼ .07), 90-day stroke (OR, 1.1; 95% CI, 0.9-1.34; P ¼ .36), 30-day MI (OR, 1.0; 95% CI, 0.67-1.51; P ¼ .98), and 90-day MI (OR, 1.02; 95% CI, 0.78-1.34; P ¼ .89). Use of high-dose compared to standard-dose statin therapy did not affect 30-day stroke (OR, 1.02; 95% CI, 0.55-1.91; P ¼ .94), 90-day stroke (OR, 1.06; 95% CI, 0.75-1.5; P ¼ .73), 30-day MI (OR, 0.79; 95% CI, 0.3-2.1; P ¼ .63), and 90-day MI (OR, 1.33; 95% CI, 0.84-2.09; P ¼ .22). Statin use was independently protective against longterm stroke (hazard ratio, 0.82; 95% CI, 0.74-0.91; P < .001) and MI (hazard ratio, 0.8; 95% CI, 0.72-0.89; P < .001) throughout the duration of insurance coverage.
Conclusions: Although statin therapy was associated long-term with lower stroke and MI, it did not affect 30-and 90-day outcomes. Highintensity statin use was not associated with improved 30-and 90-day outcomes after CEA.
Author Disclosures: N. Arinze: Nothing to disclose; A. Farber: Nothing to disclose; J. Kalish: Nothing to disclose; G. Kasotakis: Nothing to disclose; A. H. Kuhnen: Nothing to disclose; G. Patts: Nothing to disclose; T. Sachs: Nothing to disclose; J. J. Siracuse: Cook Peripheral. Objectives: In-stent restenosis (ISR) after carotid artery stenting (CAS) is a relatively common complication (range, 5%-12%). Usually, a new endovascular intervention is proposed to treat ISR, but catheter-based procedures reveal unsatisfactory long-term results, and in some cases, stent removal and carotid reconstruction are required. The aim of the present 
IP117.

Symptomatic Intrastent Carotid
86S Abstracts
Journal of Vascular Surgery
June Supplement 2017
